title: Atherogenic dyslipidemia: prevalence and management in lipid clinics.
abstract: OBJECTIVE
  Atherogenic dyslipidemia, which is characterized by increased triglyceride levels and reduced HDL cholesterol levels, is underestimated and undertreated in clinical practice. We assessed its prevalence and the achievement of therapeutic objectives for HDL cholesterol and triglyceride levels in patients treated at lipid and vascular risk units in Spain.
  
  
  METHODS
  This was an observational, longitudinal, retrospective, multicenter study performed in 14 autonomous Spanish communities that consecutively included 1828 patients aged ≥18 years who were referred for dyslipidemia and vascular risk to 43 lipid clinics accredited by the Spanish Society of Arteriosclerosis. We collected information from the medical records corresponding to 2 visits conducted during 2010 and 2011-12, respectively.
  
  
  RESULTS
  Of the 1649 patients who had a lipid profile in the first visit (90.2%), 295 (17.9%) had atherogenic dyslipidemia. The factors associated with atherogenic dyslipidemia were excess weight/obesity, not taking hypolipidemic drugs (statins and/or fibrates), diabetes, myocardial infarction and previous heart failure. Of the 273 (92.5%) patients with atherogenic dyslipidemia that had a lipid profile in the last visit, 44 (16.1%) achieved the therapeutic objectives for HDL cholesterol and triglyceride levels. The predictors of therapeutic success were normal weight and normoglycemia.
  
  
  CONCLUSIONS
  One of every 6 patients treated in lipid and vascular risk units had atherogenic dyslipidemia. The degree to which the therapeutic goals for HDL cholesterol and triglyceride levels were achieved in these patients was very low.
authors.affiliation: Unidad de Lípidos y Riesgo Vascular, Servicio de Endocrinología y Nutrición, Hospital del Mar, Universitat Autònoma de Barcelona, Barcelona, España. Electronic address: 86620@parcdesalutmar.cat.
authors.forename: J
authors.initials: J
authors.lastname: Pedro-Botet
authors.affiliation: Unidad de Lípidos y Riesgo Vascular, Servicio de Endocrinología y Nutrición, Hospital del Mar, Universitat Autònoma de Barcelona, Barcelona, España.
authors.forename: J A
authors.initials: JA
authors.lastname: Flores-Le Roux
authors.affiliation: Servicio de Medicina Interna, Hospital Carlos III, Madrid, España.
authors.forename: J M
authors.initials: JM
authors.lastname: Mostaza
authors.affiliation: Unidad de Lípidos, Servicio de Medicina Interna, Hospital Universitario de Bellvitge, Universitat de Barcelona, CIBERobn-ISCIIIBarcelona, España.
authors.forename: X
authors.initials: X
authors.lastname: Pintó
authors.affiliation: Departamento de Medicina Preventiva y Salud Pública, Universidad Autónoma de Madrid/IdiPAZ CIBERESP, Madrid, España.
authors.forename: J J
authors.initials: JJ
authors.lastname: de la Cruz
authors.affiliation: Departamento de Medicina Preventiva y Salud Pública, Universidad Autónoma de Madrid/IdiPAZ CIBERESP, Madrid, España.
authors.forename: J R
authors.initials: JR
authors.lastname: Banegas
keywords: Atherogenic dyslipidemia; Cardiovascular risk prevention; Colesterol HDL; Dislipemia aterogénica; Epidemiology; Epidemiología; HDL cholesterol; Lipid clinics; Prevención cardiovascular; Triglicéridos; Triglycerides; Unidades de lípidos